Skip to main content

Table 3 Chemotherapy regimens used in the Clearview Cancer Institute in Huntsville and Roswell Park Cancer Institute cohorts

From: TLE3 as a candidate biomarker of response to taxane therapy

Regimen

Number

CCIH

 

   AC

44

   CAF

22

   AC + pT

43

   AC + dT

11

   A + dT

7

   CAF + pT

2

   AC + pT + dT

2

   CMF

72

RPCI

 

   AC

17

   AC + pT

33

   AC + dT

12

   pTa

1

   P + pTa

1

  1. Since the Roswell Park Cancer Institute (RPCI) cohort had more standardized treatment (97% had AC or AC + T), the two patients who did not receive AC as part of their regimen were filtered from the analysis. aPatients not included in the analysis. A, doxorubicin; AC, doxorubicin + cyclophosphamide; CAF, cyclophosphamide, doxorubicin, and 5-fluorouracil; CCIH, Clearview Cancer Institute in Huntsville; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; dT, docetaxel; P, carboplatin. pT, paclitaxel; T, taxane (paclitaxel or docetaxel).
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us